Literature DB >> 24275855

Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer.

Abigale Lade1, Luke A Noon, Scott L Friedman.   

Abstract

PURPOSE OF REVIEW: We review accumulating evidence that nonalcoholic steatohepatitis (NASH), a more advanced form of nonalcoholic fatty liver disease (NAFLD), predisposes patients to the risk of developing hepatocellular carcinoma (HCC), and we summarize recent advances in the elucidation of cancer-promoting pathways in NASH. We highlight the potential role of progenitor cells and hepatic stellate cells (HSCs) in promoting the early events that could culminate in cancer, as well as the emerging contribution of the gut-liver axis in promoting inflammation, senescence, and tumor growth in NASH and HCC. Finally, we review the role of bile acid receptors, vitamin D, and protective cellular pathways such as autophagy. RECENT
FINDINGS: Studies have recently uncovered roles for gut microbiota, bile acid receptors and vitamin D in regulating the progression from NAFLD to HCC. Intriguing findings linking senescence and autophagy in hepatic stellate cells to HCC have also been discovered, as well as a link between dysregulated progenitor cell regulation and HCC.
SUMMARY: NAFLD is the most common cause of chronic liver disease in the United States and Western Europe. The lack of definitive mechanisms underlying development of NASH among patients with NAFLD and its progression to HCC limit diagnosis and management, but new findings are paving the way for better biomarkers and therapies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24275855      PMCID: PMC4474366          DOI: 10.1097/CCO.0000000000000042

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  90 in total

1.  Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.

Authors:  Naga P Chalasani; Arun J Sanyal; Kris V Kowdley; Patricia R Robuck; Jay Hoofnagle; David E Kleiner; Aynur Unalp; James Tonascia
Journal:  Contemp Clin Trials       Date:  2008-09-10       Impact factor: 2.226

2.  Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice.

Authors:  Marc-Emmanuel Dumas; Richard H Barton; Ayo Toye; Olivier Cloarec; Christine Blancher; Alice Rothwell; Jane Fearnside; Roger Tatoud; Véronique Blanc; John C Lindon; Steve C Mitchell; Elaine Holmes; Mark I McCarthy; James Scott; Dominique Gauguier; Jeremy K Nicholson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-08       Impact factor: 11.205

3.  Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease.

Authors:  Cynthia D Guy; Ayako Suzuki; Marzena Zdanowicz; Manal F Abdelmalek; James Burchette; Aynur Unalp; Anna Mae Diehl
Journal:  Hepatology       Date:  2012-04-18       Impact factor: 17.425

4.  Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease.

Authors:  Valerio Nobili; Guido Carpino; Anna Alisi; Antonio Franchitto; Gianfranco Alpini; Rita De Vito; Paolo Onori; Domenico Alvaro; Eugenio Gaudio
Journal:  Hepatology       Date:  2012-12       Impact factor: 17.425

Review 5.  Mechanisms of disease progression in nonalcoholic fatty liver disease.

Authors:  Janice Jou; Steve S Choi; Anna Mae Diehl
Journal:  Semin Liver Dis       Date:  2008-10-27       Impact factor: 6.115

6.  The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease.

Authors:  Silvia Sookoian; Gustavo O Castaño; Adriana L Burgueño; Tomas Fernández Gianotti; María Soledad Rosselli; Carlos Jose Pirola
Journal:  Pharmacogenet Genomics       Date:  2010-01       Impact factor: 2.089

Review 7.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.

Authors:  Donna L White; Fasiha Kanwal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-04       Impact factor: 11.382

Review 8.  Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications.

Authors:  Elisa Fabbrini; Shelby Sullivan; Samuel Klein
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

9.  Peripheral intrahepatic cholangiocarcinoma occurring in patients without cirrhosis or chronic bile duct diseases: epidemiology and histopathology of distant nontumoral liver in 57 White patients.

Authors:  Gisèle Nkontchou; Jeanne Tran Van Nhieu; Marianne Ziol; Iulia Tengher; Amel Mahmoudi; Dominique Roulot; Valérie Bourcier; Nathalie Ganne Carrie; Véronique Grando-Lemaire; Jean-Claude Trinchet; Daniel Cherqui; Michel Beaugrand
Journal:  Eur J Gastroenterol Hepatol       Date:  2013-01       Impact factor: 2.566

10.  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.

Authors:  Jorge Henao-Mejia; Eran Elinav; Chengcheng Jin; Liming Hao; Wajahat Z Mehal; Till Strowig; Christoph A Thaiss; Andrew L Kau; Stephanie C Eisenbarth; Michael J Jurczak; Joao-Paulo Camporez; Gerald I Shulman; Jeffrey I Gordon; Hal M Hoffman; Richard A Flavell
Journal:  Nature       Date:  2012-02-01       Impact factor: 49.962

View more
  30 in total

Review 1.  Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes.

Authors:  Yuan-Chi Teng; Zhao-Qing Shen; Cheng-Heng Kao; Ting-Fen Tsai
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 2.  Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD.

Authors:  Helen L Reeves; Marco Y W Zaki; Christopher P Day
Journal:  Dig Dis Sci       Date:  2016-02-26       Impact factor: 3.199

3.  Dual Shp2 and Pten Deficiencies Promote Non-alcoholic Steatohepatitis and Genesis of Liver Tumor-Initiating Cells.

Authors:  Xiaolin Luo; Rui Liao; Kaisa L Hanley; Helen He Zhu; Kirsten N Malo; Carolyn Hernandez; Xufu Wei; Nissi M Varki; Nazilla Alderson; Catherine Chu; Shuangwei Li; Jia Fan; Rohit Loomba; Shuang-Jian Qiu; Gen-Sheng Feng
Journal:  Cell Rep       Date:  2016-12-13       Impact factor: 9.423

4.  CD11c+ resident macrophages drive hepatocyte death-triggered liver fibrosis in a murine model of nonalcoholic steatohepatitis.

Authors:  Michiko Itoh; Takayoshi Suganami; Hideaki Kato; Sayaka Kanai; Ibuki Shirakawa; Takeru Sakai; Toshihiro Goto; Masahiro Asakawa; Isao Hidaka; Hiroshi Sakugawa; Koji Ohnishi; Yoshihiro Komohara; Kenichi Asano; Isao Sakaida; Masato Tanaka; Yoshihiro Ogawa
Journal:  JCI Insight       Date:  2017-11-16

Review 5.  Pathobiology of liver fibrosis: a translational success story.

Authors:  Youngmin A Lee; Michael C Wallace; Scott L Friedman
Journal:  Gut       Date:  2015-02-13       Impact factor: 23.059

Review 6.  Mechanisms of hepatic stellate cell activation.

Authors:  Takuma Tsuchida; Scott L Friedman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-05-10       Impact factor: 46.802

7.  Hepatocyte-specific, PPARγ-regulated mechanisms to promote steatosis in adult mice.

Authors:  Abigail Wolf Greenstein; Neena Majumdar; Peng Yang; Papasani V Subbaiah; Rhonda D Kineman; Jose Cordoba-Chacon
Journal:  J Endocrinol       Date:  2016-10-31       Impact factor: 4.286

8.  Hepatocellular carcinoma in non-alcoholic fatty liver disease (NAFLD) - pathological evidence for a predominance of steatohepatitic inflammatory non-proliferative subtype.

Authors:  Priscila B de Campos; Claudia P Oliveira; José T Stefano; Sebastião N Martins-Filho; Aline L Chagas; Paulo Herman; Luiz C D'Albuquerque; Mário R Alvares-da-Silva; Adhemar Longatto-Filho; Flair J Carrilho; Venancio A F Alves
Journal:  Histol Histopathol       Date:  2019-12-20       Impact factor: 2.303

9.  Growth Hormone Inhibits Hepatic De Novo Lipogenesis in Adult Mice.

Authors:  Jose Cordoba-Chacon; Neena Majumdar; Edward O List; Alberto Diaz-Ruiz; Stuart J Frank; Anna Manzano; Ramon Bartrons; Michelle Puchowicz; John J Kopchick; Rhonda D Kineman
Journal:  Diabetes       Date:  2015-05-26       Impact factor: 9.461

10.  Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease.

Authors:  Stefan Traussnigg; Emina Halilbasic; Harald Hofer; Petra Munda; Tatjana Stojakovic; Günter Fauler; Karl Kashofer; Martin Krssak; Michael Wolzt; Michael Trauner
Journal:  Wien Klin Wochenschr       Date:  2020-09-15       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.